Geneva, July 22 -- International Clinical Trials Registry received information related to the study (NCT06739122) titled 'A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)' on Dec. 13, 2024.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Eli Lilly and Company
Condition:
Type 2 Diabetes
Intervention:
Drug: Dulaglutide
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: January 10, 2025
Target Sample Size: 55
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/sh...